Nibrin expression in oral squamous cell carcinoma: association with clinicopathological parameters

Abstract

Aim: The present study sought to discover the role of Nibrin protein in 100 patients with oral squamous cell carcinoma (OSCC) and its potential relationship with clinicopathological parameters.

Methods: Nibrin expression was evaluated immunohistochemically using the modified H-score method.

Results: The present study included 20% of patients with stage I disease, 22% of patients with stage II disease, 18% of patients with stage III disease, and 40% of patients with stage IV disease. Nibrin showed a significant positive correlation with moderately/poorly differentiated tumor tissues (P = 0.028), while significant inverse correlation of Nibrin expression was observed with tumor size (P = 0.018) and tumor stage (P = 0.039). Further, using univariate survival analysis it was observed that strong Nibrin expression was significantly associated with disease relapse in early stage OSCC patients (P = 0.049).

Conclusion: Thus, the present study revealed that Nibrin could be used as a prognostic marker in patients with early stage OSCC.

Keywords

Nibrin protein expression / oral squamous cell carcinoma / clinicopathological parameters

References

[1] Bettendorf O,Bànkfalvi A.Prognostic and predictive factors in oral squamous cell cancer: important tools for planning individual therapy?.Oral Oncol2004;40:110-9

[2] Nagler RM.Molecular aspects of oral cancer..Anticancer Res2002;22:2977-80

[3] Zbären P.Frequency and sites of distant metastases in head and neck squamous cell carcinoma. An analysis of 101 cases at autopsy..Arch Otolaryngol Head Neck Surg1987;113:762-4

[4] Neville BW.Oral cancer and precancerous lesions..CA Cancer J Clin2002;52:195-215

[5] Feller L.Oral squamous cell carcinoma: epidemiology, clinical presentation and treatment..J Cancer Ther2012;3:263-8

[6] Facompre N,Herlyn M.Stem-like cells and therapy resistance in squamous cell carcinomas..Adv Pharmacol2012;65:235-65 PMCID:PMC3595160

[7] Cohen EE.Novel therapeutic targets in squamous cell carcinoma of the head and neck..Semin Oncol2004;31:755-68

[8] Scully C,Tanzawa H.Genetic aberrations in oral or head and neck squamous cell carcinoma 3: clinicopathological applications..Oral Oncol2000;36:404-13

[9] Nagpal JK.Oral cancer: reviewing the present understanding of its molecular mechanisms and exploring the future directions for its effective management..Oral Oncol2003;39:213-21

[10] Nagai MA.Genetic alterations in head and neck squamous cell carcinomas..Braz J Med Biol Res1999;32:897-904

[11] Vilenchik MM.Inverse radiation dose-rate effects on somatic and germ-line mutations and DNA damage rates..Proc Natl Acad Sci U S A2000;97:5381-6 PMCID:PMC25837

[12] Arnott RD.What risk premium is "normal"?.Financial Analyst J2002;58:64-85

[13] Petrini JH.The Mre11 complex and ATM: collaborating to navigate S phase..Curr Opin Cell Biol2000;12:293-6

[14] Karran P.DNA double strand break repair in mammalian cells..Curr Opin Genet Dev2000;10:144-50

[15] D'Amours D.The Mre11 complex: at the crossroads of DNA repair and checkpoint signaling..Nat Rev Mol Cell Biol2002;3:317-27

[16] Cerosaletti KM,Stringham HM,Smeets D,Belohradsky BH,Karnes P,Komatsu K,Boehnke M.Fine localization of the Nijmegen breakage syndrome gene to 8q21: evidence for a common founder haplotype..Am J Hum Genet1998;63:125-34 PMCID:PMC1377248

[17] Nelms BE,MacKay JF,Petrini JH.In situ visualization of DNA double-strand break repair in human fibroblasts..Science1998;280:590-2

[18] Pandita TK,Geard CR.Chromosome end associations, telomeres and telomerase activity in ataxia telangiectasia cells..Cytogenet Cell Genet1995;71:86-93

[19] Metcalfe JA,Campbell L,Biggs P,Taylor AM.Accelerated telomere shortening in ataxia telangiectasia..Nat Genet1996;13:350-3

[20] Lim DS,Xu B,Lin J,Kastan MB.ATM phosphorylates p95/nbs1 in an S-phase checkpoint pathway..Nature2000;404:613-7

[21] Zhao S,Yuan SS,Hsu HC,Gerbino E,Zdzienicka MZ,Shay JW,Shiloh Y.Functional link between ataxia-telangiectasia and Nijmegen breakage syndrome gene products..Nature2000;405:474-7

[22] Wu X,Weisman DS,Ciccone DN,Crick KE,Lane WS,Livingston DM.ATM phosphorylation of Nijmegen breakage syndrome protein is required in a DNA damage response..Nature2000;405:477-82

[23] Stumm M,Siebert R,Varon R,Schlegelberger B.No evidence for deletions of the NBS1 gene in lymphomas..Cancer Genet Cytogenet2001;26:60-2

[24] Varon R,Henze G,Sperling K.Mutations in the Nijmegen Breakage syndrome gene (NBS1) in childhood acute lymphoblastic leukemia (ALL)..Cancer Res2001;61:3570-2

[25] Plisiecka-Halasa J,Rembiszewska A,Steffen J.Nijmegen breakage syndrome gene (NBS1) alterations and its protein (nibrin) expression in human ovarian tumors..Ann Hum Genet2002;66:353-9

[26] Wilda M,Concannon P,Hameister H.Expression pattern of the Nijmegen breakage syndrome gene, Nbs1, during murine development..Hum Mol Genet2000;9:1739-44

[27] Featherstone C.DNA repair: The Nijmegen breakage syndrome protein..Curr Biol1998;8:622-5

[28] Digweed M,Sperling K.Nijmegen breakage syndrome: consequences of defective DNA double strand break repair..Bioessays1999;21:649-56

[29] Stracker TH.The MRE11 complex: starting from the ends..Nat Rev Mol Cell Biol2011;12:90-103 PMCID:PMC3905242

[30] Hsu DS,Liu CJ,Wu KJ,Yang MH.Identification of increased NBS1 expression as a prognostic marker of squamous cell carcinoma of the oral cavity..Cancer Sci2010;101:1029-37

[31] Ali-Fehmi R,Ionan A,Arabi H,Shah JP,Hewitt SM,Alekseev OM,Munkarah A,Tainsky MA.Analysis of the expression of human tumor antigens in ovarian cancer tissues..Cancer biomark2010;6:33-48 PMCID:PMC3343030

[32] Hall J.Radiation, DNA damage and cancer..Mol Med Today1999;5:157-64

[33] Ehlers JP.NBS1 expression as a prognostic marker in uveal melanoma..Clin Cancer Res2005;11:1849-53

[34] Angèle S,Brémond A,Hall J.Altered expression of DNA double-strand break detection and repair proteins in breast carcinomas..Histopathology2003;43:347-53